SRP1020

Shanghai SciBrunch Therapeutics Co., Ltd. · Phase 1 active Small molecule

At a glance

Generic name	SRP1020
Sponsor	Shanghai SciBrunch Therapeutics Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SRP1020 CI brief — competitive landscape report
SRP1020 updates RSS · CI watch RSS
Shanghai SciBrunch Therapeutics Co., Ltd. portfolio CI